title: Chemoprevention in Barrett's Esophagus: Current Status.
abstract: Chemoprevention in Barrett's esophagus is currently applied only in research settings. Identifying pathways that can be targeted by safe, pharmaceutical or natural compounds is key to expanding the scope of chemoprevention. Defining meaningful surrogate markers of cancer progression is critical to test the efficacy of chemopreventive approaches. Combinatorial chemoprevention that targets multiple components of the same pathway or parallel pathways could reduce the risk and improve the efficacy of chemoprevention. Here we discuss the role of chemoprevention as an independent or an adjuvant management option in BE-associated esophageal adenocarcinoma.
authors.affiliation: Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA.
authors.forename: Muhammad H
authors.initials: MH
authors.lastname: Zeb
authors.affiliation: Department of Internal Medicine, John H. Stroger, Jr. Hospital of Cook County, 1901 W. Harrison Street, Chicago, IL 60612, USA.
authors.forename: Anushka
authors.initials: A
authors.lastname: Baruah
authors.affiliation: Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA.
authors.forename: Sarah K
authors.initials: SK
authors.lastname: Kossak
authors.affiliation: Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA. Electronic address: buttar.navtej@mayo.edu.
authors.forename: Navtej S
authors.initials: NS
authors.lastname: Buttar
mesh_terms: D000230:Adenocarcinoma / Q000517:prevention & control*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D001471:Barrett Esophagus / Q000473:pathology / Q000517:prevention & control*; D001647:Bile Acids and Salts / Q000378:metabolism; D016207:Cytokines / Q000378:metabolism; D055808:Drug Discovery; D004938:Esophageal Neoplasms / Q000517:prevention & control*; D005231:Fatty Acids, Unsaturated / Q000008:administration & dosage; D005764:Gastroesophageal Reflux / Q000188:drug therapy; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007249:Inflammation / Q000378:metabolism; D024821:Metabolic Syndrome / Q000378:metabolism; D008687:Metformin / Q000627:therapeutic use; D009765:Obesity / Q000150:complications / Q000378:metabolism; D065108:Ornithine Decarboxylase Inhibitors / Q000627:therapeutic use; D011230:Precancerous Conditions / Q000517:prevention & control*; D054328:Proton Pump Inhibitors / Q000627:therapeutic use; D015398:Signal Transduction
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D001647:Bile Acids and Salts; D016207:Cytokines; D005231:Fatty Acids, Unsaturated; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007004:Hypoglycemic Agents; D065108:Ornithine Decarboxylase Inhibitors; D054328:Proton Pump Inhibitors; D008687:Metformin
keywords: Barrett’s esophagus; Chemoprevention; Chronic reflux; Esophageal adenocarcinoma